Erdal KURTOĞLU, Ayşegül UĞUR, LEVENT ÜNDAR

Hematolojik malignitelerde plazma thrombospondin düzeyleri

Amaç: Trombospondin (TSP) trombositler, megakaryositler, endotel hücreleri, düz kas hücreleri, fibroblastlar, pnömositler, makrofajlar, monositler ve tümör hücreleri tarafından salgılanan adhesiv özellik gösteren bir glikoproteindir. TSP'nin tümör metastazında çok önemli oynadığı bilinmektedir. Çalışmamızda hematolojik malignitesi olan olguların plazma TSP düzeyini sağlıklı bireylerle ve tanılarına göre birbirleri ile kıyaslamayı amaçladık. Yöntem: Bu çalışmada 53 hematolojik maligniteli hasta ile 31 sağlıklı erişkinin plazma TSP düzeyleri "sandwich ELlZA" yöntemi ile ölçülerek kıyaslanmıştır. Bulgular: Tüm hastalar ele alındığında hastaların serum TSP düzeyi sağlıklı bireylerinkinden farksız bulundu (P=0.97). Kontrol grubu da dahil olmak üzere tüm grupların analizi, gruplar arasında TSP düzeyi açısından anlamlı bir fark olmadığını gösterdi (P=0.21). MDS/KML grubunun median TSP düzeyi AML grubununkinden anlamlı olarak yüksek bulundu (P=0.045). Kontrol grubu da dahil olmak üzere tüm altgruplarm analizi, altgruplar arasında TSP düzeyi açısından anlamlı bir fark olduğunu gösterdi (P=0.0024). Sonuç: Hematolojik malignitelerde solid malignitelerden farklı olarak normal ya da düşük plazma TSP düzeyleri ile karşılaşmamız sürpriz oldu. Açıklayıcı yorumlarda bulunabilmek için hasta sayısının daha çok olduğu çalışmaların yapılması gereklidir. Plazma TSP düzeylerindeki düşüklük hematolojik malignitelerin biyolojilerinin solid malignitelerin biyolojilerinden farklılığının bir göstergesi olarak da ele alınabilir.

Anahtar Kelimeler:

Trombospondinler, Multipl miyelom, Lenfom, Hematolojik neoplazmlar

Plasma thrombospondin levels in hematologic malignancies

Objective: Thrombospondin (TSP) is an adhesive glycoprotein secreted by different types of cells, namely thrombocytes, endothelial cells, smooth muscle cells, fibroblasts, macrophages, monocytes and tumor cells. It is well-known that TSP plays an important role in tumor metastasis. We aimed to compare plasma TSP levels of patients with hematologic malignancies to normal healthy ones and with each other according to different diagnosis. Methods: In this study plasma TSP levels of 53 patients with hematological malignancy and 31 healthy controls were measured by sandwich ELISA method and then compared. Results: Overall plasma TSP levels of patients were not different from those of healthy controls (P=0.97). Overall analysis of all groups including controls revealed no difference of plasma TSP levels (P=0.21). Furthermore pairwise comparison of groups showed that median plasma TSP level of MDS/KML group was significantly high in comparison to that of acute leukemia group (P=0.045). Overall analysis plasma TSP levels of all subgroups including controls revealed a significant difference among them (P=0.0024). Conclusion: We are surprised by low plasma TSP levels in hematological malignancies unlike solid malignancies. Studies holding more patients are needed. Actually low plasma levels of TSP may be an indicator of the biological difference between hematologic and solid malignancies.

Keywords:

Thrombospondins, Multiple Myeloma, Lymphoma, Hematologic Neoplasms,

PDF

___

1. Frazier WA. Thrombospondin: A modular adhesive glycoprotein of platelets and nucleated cells. J Cell Biol 1987;105:625-32.
2. Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 1996;10:1183-91.
3. Tuszynski GP, Rothman V, Murphy A, Siegler K, Smith L. Thrombospondin promotes cell-substratum adhesion. Science 1987;236:1570-3.
4. Hosokawa T, Murasisi A, Rothman VL, Papale M, Tuszynski GP. The effect of thrombospondin on invasion of fibrin gels by human A549 lung carcinoma. Oncol Res 1993;5:5183-9.
5. Tuszynski GP, Smith M, Rothman VL, Capuzzi DD, Joseph RR, Katz J. Thrombospondin levels in patients with malignancy. Thromb Haemost 1992;67:607-11.
6. Nathan FE, Hernandez E, Dunton CJ, Treat J, Switalska HI, Joseph RR, et al. Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer 1994;73:2853-8.
7. Özatlı D, Koçoğlu H, Haznedaroğlu İC, Koşar A, Büyükaşık Y, Özcebe O, et al. Circulating thrombomodulin, thrombospondin and fibronectin in acute myeloblastic leukemias. Hematologia 1999;29:277-83.
8. Switalska HI, Niewiarowski S, Tuszynski GP, Rucinski B, Schmaier AH, Morinelli TA, et al. Radioimmunoassay of human platelet thrombospondin: Different patterns of thrombospondin and b-thromboglobolin antigen secretion and clearance from the circulation. J Lab Clin Med 1985;106:690-700.
9. Pratt DA, Miller WR, Dawes J. Thrombospondin in malignant and non-malignant breast tissue. Eur J Cancer Clin Oncol 1989;25:343-50.
10. Grinnel RS. The lymphatic and venous spread of carcinoma of the rectum. Ann Surg 1942;116:200-16.
11. Carrol SE. The prognostic significance of gross venous invasion in carcinoma of the rectum. Can J Surg 1963;6:281-8.
12. Khankahnian N, Mavligit GM, Russell WO, Schimek M. Prognostic significance of vascular invasion in colorectal cancer of Dukes’ B class. Cancer 1977;39:1195-200.
13. Talbot IC, Ritchie S. The clinical significance of invasion of veins by rectal cancer. Br J Surg 1980;67:439-42.
14. Minsky BD, Mies C. The clinical significance of vascular invasion in colorectal cancer. Dis Colon Rectum 1989;32:794-803.
15. Krasna MJ, Flancbaum L, Cody RP, Shneibaum S, Ari GB. Vascular and neural invasion in colorectal carcinoma: Incidence and prognostic significance. Cancer 1988;61:1018-23.
16. Yamashita Y, Kurohiji T, Tuszynski GP, Sakai T, Shirakusa T. Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer 1998;82:632-8.
17. Oshiba G, Kijima H, Himeno S, Kenmochi T, Kise Y. Stromal thrombospondin-1 expression is correlated with progression of esophageal squamous cell carcinomas. Anticancer Res 1999;19(5C):4375-8.
18. Hamamoto K, Ohga S, Nagano T, Kishimoto Y, Yasunaga K, Sato T. Expression of platelet alpha-granule proteins in a human megakaryocytic leukemia cell line (CMK 11-5). Int J Hematol 1993;58:105-12.
19. Ryo R, Yoshida A, Yamaguchi N. Megakaryocytic leukemia cell lines and megakaryocytic leukemia. Rinsho Byori 1999;38:514-23.
20. Dawes J, Pratt DA, Dewar MS, Preston FE. Do extra-platelet sources contribute to the plasma level of thrombospondin? Thromb Haemost 1988;59:276-81.
21. Imamura N, Mtasiwa DM, Inada T, Kuramoto A. Different expression of CD36 antigen molecule on the surface of megakaryocyte lineage leukemias and megakaryocyte leukemia cell lines MEG-01 and HEL. Leukemia 1990;4:525-8.
22. Ikeda H, Platelet membrane protein CD36. Hokkaido Igaku Zasshi 1999;74:99-104.
23. Tsuchida T, Kijima H, Tokunaga T, Oshika Y, Hatanaka H. Expression of the thrombospondin receptor CD36 is correlated with decreased stromal vascularisation in colon cancer. Int J Oncol 1999;14:47-51.
24. Daviet L, McGregor JL. Vascular biology of CD36: Roles of this new adhesion molecule family in different disease states. Thromb Haemost 1997;78:65-9.
25. Rutella S, Rumi C, Puggioni P, Barberi T, Di Mario A, Larocca LM, et al. Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination. Haematologica 1999;84:419-24.
26. Van Riet I, Vanderkerken K, de Greef C, Van Camp B. Homing behavior of the malign cell clones in multiple myeloma. Med Oncol 1998;1:154-64.
27. Van Riet I. Homing mechanisms of myeloma cells. Pathol Biol 1999;47:98-108.
28. Van Camp B, Van Riet I. Homing mechanism in biology of multiple myeloma. Verh K Acad Geneeskd Belg 1998;60:163-94.
29. Kibler C, Schermutzki F, Waller HD, Timpl R, Mullar CA, Klein G. Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix proteins. Cell Adhes Commun 1998;5:307-23.
30. Pals ST, Drillenburg P, Radaskiewicz T, Manten-Horst E. Adhesion molecules in the dissemination of non-Hodgkin’s lymphomas. Acta Haematol 1997;97:73-80.
31. Dvorak HF. Leaky tumor vessels: Consequences for tumor stroma generation and for solid tumor therapy. Prog Clin Biol Res 1990;354A:317-30.
32. Edwards RL, Rickles FR. Hemostatic alterations in cancer patients. In: Honn JV, Sloane BF, editors. Hemostatic Mechanisms and Metastasis. Martinus Nijhoff, Boston 1984; p 343.
33. Arnoletti JP, Albo D, Granick MS, Solomon MP, Castiglioni A. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer. Cancer 1995;76:998-1005.

ISSN: 2602-3741
Yayın Aralığı: Yılda 6 Sayı
Başlangıç: 1997
Yayıncı: SELÇUK ÜNİVERSİTESİ > TIP FAKÜLTESİ

Arşiv